Network-Based Drug Discovery: Coupling Network Pharmacology with Phenotypic Screening for Neuronal Excitability.

J Mol Biol

Neusentis, Pfizer Research & Development, Cambridge, CB21 6GS, UK; Mission Therapeutics, Cambridge, CB22 3AT, UK.

Published: September 2018

Diseases such as chronic pain with complex etiologies are unlikely to respond to single, target-specific therapeutics but rather require intervention at multiple points within a perturbed disease system. Such approaches are being enabled by the rise of computational methods to identify key points of intervention and by new screening techniques that focus on a relevant condition or phenotype, rather than a specific target. Here we apply an in silico network pharmacology approach to identify small-molecule compounds with the potential to selectively disrupt the structure of a chronic-pain specific disease network, which we validate using a novel phenotypic screen that recapitulates key aspects of neuronal and pain biology by measuring changes in neuronal excitability in native sensory neurons. The combination of network pharmacology with a phenotypic screen is a powerful approach; we show that hit rates increase from 26% to 42%. This represents a rational approach to the discovery of compounds with a poly-pharmacology based therapeutic value, which will be vital for the discovery of treatments for complex disease.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmb.2018.07.016DOI Listing

Publication Analysis

Top Keywords

network pharmacology
12
pharmacology phenotypic
8
neuronal excitability
8
phenotypic screen
8
network-based drug
4
drug discovery
4
discovery coupling
4
network
4
coupling network
4
phenotypic screening
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!